Who is sponsoring NCT06592690?

NCT06592690 is sponsored by Ospedale Centrale Bolzano.

What drugs are being tested in NCT06592690?

Interventions in NCT06592690: Atrial pacing support, Atrial tracking pacing mode.

What condition does NCT06592690 study?

NCT06592690 studies Heart Failure, Wide QRS Complex.

Is NCT06592690 still recruiting?

NCT06592690 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06592690

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Rate-responsive Compared to VDD Pacing in Cardiac Resynchronization Therapy Recipients

Completed NA Last updated 19 September 2024

What this trial tests

NA trial testing Atrial pacing support in Heart Failure, Wide QRS Complex in 26 participants. Completed in 17 September 2021.

Timeline

27 November 2017

Primary endpoint
17 September 2021

17 September 2021

Quick facts

Lead sponsor	Ospedale Centrale Bolzano
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	26
Start date	27 November 2017
Primary completion	17 September 2021
Estimated completion	17 September 2021
Sites	1 location across Italy

Drugs / interventions tested

Atrial pacing support
Atrial tracking pacing mode

Conditions studied

Heart Failure, Wide QRS Complex — all drugs for Heart Failure, Wide QRS Complex →

Sponsor

Ospedale Centrale Bolzano

Who can join

18 and older, any sex, with Heart Failure, Wide QRS Complex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to understand the best programming pacing mode for cardiac resynchronization therapy devices used to treat chronic heart failure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of rate-adaptive atrial support compared to VDD pacing in cardiac resynchronization therapy recipients: A randomized cross-over study.
Donazzan L, Bulian F, Maines M, Erckert M, et al · · 2025 · PMID 39701488 · DOI 10.1016/j.ahj.2024.12.005

Verify or expand the search:

Other Ospedale Centrale Bolzano trials

Trials by the same sponsor.

NCT05716815 — Prospective rAndomized sTudy efficaCy tHree-dimensional rEconstructions Segmentectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06592690 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ospedale Centrale Bolzano
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing